Pfizer to buy obesity drug developer Metsera, beating Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral and injectable treatments for obesity and diabetes. On Friday, M
(Associated Press, 2025-11-08T17:34:13Z)